<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424707</url>
  </required_header>
  <id_info>
    <org_study_id>DW340-P2</org_study_id>
    <nct_id>NCT03424707</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain</brief_title>
  <official_title>A Single-Center, Randomized, Double-Blind, Parallel, Pilot Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-Center, Randomized, Double-Blind, Parallel, Pilot Study to Evaluate the Efficacy and&#xD;
      Safety of Fixed Dose Combination of Pelubiprofen/Eperisone in Patients with Acute Low Back&#xD;
      Pain&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2016</start_date>
  <completion_date type="Actual">August 30, 2016</completion_date>
  <primary_completion_date type="Actual">August 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>100mm VAS</measure>
    <time_frame>7 days</time_frame>
    <description>The change of 100mm movement pain VAS between basline and end point</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Acute Low Back Pain</condition>
  <arm_group>
    <arm_group_label>combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>single</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW340(pelubiprofen/eperisone)</intervention_name>
    <description>DW340</description>
    <arm_group_label>combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelubi(pelubiprofen)</intervention_name>
    <description>pelubiprofen</description>
    <arm_group_label>single</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo Oral Tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults over 19 years of age&#xD;
&#xD;
          2. Patients with a paraxial (muscle spasm) of less than 21 days and acute lower back&#xD;
             pain. Randomized intervention. Arterial pain 100 mm - visual analogue scale (VAS)&#xD;
&#xD;
          3. Participation and voluntary agreement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Drugs for Clinical Trial or Similar Drugs and Components with Hypersensitivity or&#xD;
             Aspirin or Nonsteroidal Anti-inflammatory Drugs&#xD;
&#xD;
          2. Those accompanying the following diseases (1) patients with severe underlying diseases&#xD;
             that cause back pain (eg, cancer, spinal infections, cauda equina syndrome, spinal&#xD;
             stenosis, neuropathy, vertebral compression fracture, posterior hiatal joint syndrome,&#xD;
             intervertebral disc herniation, fibromyalgia, Spondylolisthesis, imaging confirmed&#xD;
             degenerative spondylosis, severe arthritis or severe osteoporosis) (2) myositis,&#xD;
             muscular atrophy, myotonia, myasthenia (3) peptic ulcer or duodenal ulcer (4)&#xD;
             Gastrointestinal bleeding or bleeding disorder (5) severe heart failure (NYHA class&#xD;
             III / IV) (6) Uncontrolled hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg) (7) Liver&#xD;
             impairment (AST or ALT ≥ 3 × upper normal level of the organ) or renal impairment&#xD;
             (CLcr &lt;30 mL / min)&#xD;
&#xD;
          3. Those who have confirmed the following history or surgery / (1) lumbar surgery (2)&#xD;
             Unstable angina pectoris, myocardial infarction, transient ischemic attack, stroke,&#xD;
             coronary artery bypass surgery or coronary artery bypass graft within 6 months from&#xD;
             screening (3) galactose intolerance, Lapp lactase deficiency or glucose-galactose&#xD;
             malabsorption, (4) malignant tumor within 5 years from the screening point&#xD;
&#xD;
          4. Drugs that may affect the following efficacy evaluations during clinical trials, or&#xD;
             those expected to require drug interactions with the clinical trial drug (provided&#xD;
             there is a separate standard, such as a nonsteroidal anti-inflammatory drug) Follow&#xD;
             the standard.) (1) Nonsteroidal antiinflammatory drugs: pelubiprofen, aceclofenac,&#xD;
             diclofenac, ketorolac (from 1 week before randomization until the end of the clinical&#xD;
             trial, except oxaprozin and oxicam 2 weeks before randomization) (2) Muscle relaxants:&#xD;
             eperisone, baclofen, cyclobenzaprine, dantrolene, thiocolchicoside, tizanidine (from 1&#xD;
             week before randomization until the end of the study) (3) Analgesics: acetaminophen&#xD;
             (paracetamol), codeine, oxycodone, tramadol, etc. (However, in the case of narcotic&#xD;
             analgesics, (4) systemic or low back pain or steroids (from 4 weeks prior to&#xD;
             randomization until the end of the study) (5) Contraindications during other clinical&#xD;
             trials Drug / taboo treatment (see 7.4)&#xD;
&#xD;
          5. Pregnant or lactating women and appropriate contraceptive *&#xD;
&#xD;
             * Use of hormonal contraceptive, intrauterine devices, spouse sterilization&#xD;
             (vasectomy, tubal ligation, etc.), double blockage (use of spermicide in combination&#xD;
             with vaginal septum, vaginal sponge or neck cap)&#xD;
&#xD;
          6. Those who have received other clinical trial drugs within a longer period of 12 weeks&#xD;
             or more than half of the half-life before screening&#xD;
&#xD;
          7. Those who are unable to participate in the clinical trial according to the testee's&#xD;
             judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eperisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

